Advances in pharmacotherapy for the acute stage of acute ischemic stroke

Tang Chunhua, Zhang Lili

PDF(587 KB)
PDF(587 KB)
Journal of Chongqing Medical University ›› 2024, Vol. 49 ›› Issue (05) : 508-514. DOI: 10.13406/j.cnki.cyxb.003488
Treatment of cerebrovascular diseases

Advances in pharmacotherapy for the acute stage of acute ischemic stroke

Author information +
History +

Abstract

Stroke ranks first among the causes of death and disability in Chinese adults. Acute ischemic stroke（AIS） is the most common type of stroke that seriously affects the quality of life of patients and imposes a heavy disease burden，and therefore，the prevention and treatment of AIS is a major problem that needs to be addressed urgently. AIS has a complex pathogenesis，and overall assessment of patients should be performed to make a comprehensive decision，while following the standardized diagnosis and treatment process. There are currently two main therapeutic strategies for the acute stage of AIS，i.e.，timely recanalization of the obstructed vessels to restore the perfusion of brain tissue and rescue the ischemic penumbra and inhibition of the ischemic cascades through multiple targets to protect brain cells. In recent years，rapid progress has been made in pharmacotherapy for AIS in the fields of thrombolysis，antiplatelet therapy，and cytoprotection. With reference to related research findings in China and globally，this article reviews the advances in pharmacotherapy for the acute stage of AIS，in order to provide a scientific basis and ideas for the research and development of other effective therapeutic drugs.

Key words

acute ischemic stroke / pharmacotherapy / thrombolysis / antiplatelet therapy / cerebral protective agent

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
Tang Chunhua , Zhang Lili. Advances in pharmacotherapy for the acute stage of acute ischemic stroke. Journal of Chongqing Medical University. 2024, 49(05): 508-514 https://doi.org/10.13406/j.cnki.cyxb.003488

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis
1
Feigin VL， Brainin M， Norrving B，et al. World stroke organization （WSO）：global stroke fact sheet 2022[J]. Int J Stroke，2022，17（1）：18-29．
本文引用 [1]
2
唐春花，郭　露，李琼，等. 2022年全球卒中数据报告解读[J]. 诊断学理论与实践，2023，22（3）：238-246．
Tang CH， Guo L， Li Q，et al. Interpretation on the report of global stroke data 2022[J]. J Diagn Concepts Pract，2023，22（3）：238-246．
本文引用 [1]
3
Jiang Y， Liu ZQ， Liao Y，et al. Ischemic stroke：from pathological mechanisms to neuroprotective strategies[J]. Front Neurol，2022，13：1013083．
本文引用 [1]
4
中国卒中学会中国脑血管病临床管理指南撰写工作委员会.中国脑血管病临床管理指南[J]. 中国卒中杂志，2023,18（8）：910-933.
The Writing Committee of Chinese Stroke Association Guidelines for Clinical Management of Cerebrovascular Diseases. Chinese stroke association guidelines for clinical management of cerebrovascular diseases [J]. Chin J Stroke，2023，18（8）：910-933.
本文引用 [5]
5
Bansal S， Sangha KS， Khatri P. Drug treatment of acute ischemic stroke[J]. Am J Cardiovasc Drugs，2013，13（1）：57-69．
本文引用 [1]
6
Ye Q， Zhai FF， Chao BH，et al. Rates of intravenous thrombolysis and endovascular therapy for acute ischaemic stroke in China between 2019 and 2020[J]. Lancet Reg Health West Pac，2022，21：100406．
本文引用 [1]
7
Booyse FM， Scheinbuks J， Lin PH，et al. Isolation and interrelationships of the multiple molecular tissue-type and urokinase-type plasminogen activator forms produced by cultured human umbilical vein endothelial cells[J]. J Biol Chem，1988，263（29）：15129-15138．
本文引用 [1]
8
Robbie LA， Booth NA， Croll AM，et al. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1（PAI-1） in the inhibition of clot lysis[J]. Thromb Haemost，1993，70（2）：301-306．
本文引用 [1]
9
Warner JJ， Harrington RA， Sacco RL，et al. Guidelines for the early management of patients with acute ischemic stroke：2019 update to the 2018 guidelines for the early management of acute ischemic stroke[J]. Stroke，2019，50（12）：3331-3332．
本文引用 [2]
10
Berge E， Whiteley W， Audebert H，et al. European Stroke Organisation （ESO） guidelines on intravenous thrombolysis for acute ischaemic stroke[J]. Eur Stroke J，2021，6（1）：I-LXII．
本文引用 [2]
11
Multicenter Acute Stroke Trial--Europe Study Group， Hommel M， Cornu C，et al. Thrombolytic therapy with streptokinase in acute ischemic stroke[J]. N Engl J Med，1996，335（3）：145-150．
本文引用 [1]
12
Lee RS， Ok YC， Lim JS，et al. Outcome evaluation of intravenous infusion of urokinase for acute ischemic stroke[J]. Chonnam Med J，2012，48（1）：52-56．
本文引用 [1]
13
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke[J]. N Engl J Med，1995，333（24）：1581-1587．
本文引用 [1]
14
Merino P， Diaz A， Yepes M. Urokinase-type plasminogen activator （uPA） and its receptor（uPAR） promote neurorepair in the ischemic brain[J]. Receptors Clin Investig，2017，4（2）：e1552．
本文引用 [1]
15
Lin ZJ， Qiu HY， Tong XX，et al. Evaluation of efficacy and safety of Reteplase and Alteplase in the treatment of hyper-acute cerebral infarction[J]. Biosci Rep，2018，38（1）：BSR20170730．
本文引用 [1]
16
von Kummer R， Mori E， Truelsen T，et al. Desmoteplase 3 to 9 hours after major artery occlusion stroke：the DIAS-4 trial（efficacy and safety study of desmoteplase to treat acute ischemic stroke）[J]. Stroke，2016，47（12）：2880-2887．
本文引用 [1]
17
Campbell BCV， Mitchell PJ， Churilov L，et al. Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke：the EXTEND-IA TNK part 2 randomized clinical trial[J]. JAMA，2020，323（13）：1257-1265．
本文引用 [1]
18
Parsons M， Spratt N， Bivard A，et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke[J]. N Engl J Med，2012，366（12）：1099-1107．
本文引用 [1]
19
Huang XY， Cheripelli BK， Lloyd SM，et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke（ATTEST）：a phase 2，randomised，open-label，blinded endpoint study[J]. Lancet Neurol，2015，14（4）：368-376．
本文引用 [1]
20
Logallo N， Novotny V， Assmus J，et al. Tenecteplase versus alteplase for management of acute ischaemic stroke（NOR-TEST）：a phase 3，randomised，open-label，blinded endpoint trial[J]. Lancet Neurol，2017，16（10）：781-788．
本文引用 [1]
21
Campbell BCV， Mitchell PJ， Churilov L，et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke[J]. N Engl J Med，2018，378（17）：1573-1582．
本文引用 [1]
22
Menon BK， Buck BH， Singh N，et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada（AcT）：a pragmatic，multicentre，open-label，registry-linked，randomised，controlled，non-inferiority trial[J]. Lancet，2022，400（10347）：161-169．
本文引用 [1]
23
Alhadid K， Oliveira L， Etherton MR. Intravenous thrombolytics in the treatment of acute ischemic stroke[J]. Curr Treat Options Cardiovasc Med，2023，25（1）：15-28．
本文引用 [1]
24
Kheiri B， Osman M， Abdalla A，et al. Tenecteplase versus alteplase for management of acute ischemic stroke：a pairwise and network meta-analysis of randomized clinical trials[J]. J Thromb Thrombolysis，2018，46（4）：440-450．
本文引用 [1]
25
Wang YJ， Li SY， Pan YS，et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events（TRACE-2）：a phase 3，multicentre，open-label，randomised controlled，non-inferiority trial[J]. Lancet，2023，401（10377）：645-654．
本文引用 [1]
26
Crow J， Smith A. National Clinical Guideline for Stroke for the United Kingdom and Ireland：part I-An overview of the updated recommendations[J]. Br J Occup Ther，2023，86（10）：661-664．
本文引用 [1]
27
中国医师协会神经内科医师分会脑血管病专家组. 急性缺血性卒中替奈普酶静脉溶栓治疗中国专家共识[J]. 中国神经精神疾病杂志，2022，48（11）：641-651．
Cerebrovascular Disease Group of Neurology Sub-Association of Chinese Medical Doctor Association. Chinese expert consensus on teneplase intravenous thrombolytic therapy for acute ischemic stroke[J]. Chin J Nerv Ment Dis，2022，48（11）：641-651．
本文引用 [1]
28
Gusev EI， Martynov MY， Shamalov NA，et al. Nonimmunogenic staphylokinase in the treatment of acute ischemic stroke （FRIDA trial results）[J]. Zh Nevrol Psikhiatr Im S S Korsakova，2022，122（7）：56-65．
本文引用 [1]
29
Song HQ， Wang Y， Ma QF，et al. Efficacy and safety of recombinant human prourokinase in acute ischemic stroke：a phase IIa randomized clinical trial[J]. Transl Stroke Res，2022，13（6）：995-1004．
本文引用 [1]
30
Sillen M， Declerck PJ. A narrative review on plasminogen activator inhibitor-1 and its （patho）physiological role：to target or not to target?[J]. Int J Mol Sci，2021，22（5）：2721．
本文引用 [1]
31
Comerota AJ， Davidovic L， Hanna K，et al. Phase 2，randomized，open-label study on catheter-directed thrombolysis with plasmin versus rtPA and placebo in acute peripheral arterial occlusion[J]. J Drug Assess，2019，8（1）：43-54．
本文引用 [1]
32
Kamarova M， Baig S， Patel H，et al. Antiplatelet use in ischemic stroke[J]. Ann Pharmacother，2022，56（10）：1159-1173．
本文引用 [1]
33
Rwibasira Rudinga G， Khan GJ， Kong Y. Protease-activated receptor 4（PAR4）：a promising target for antiplatelet therapy[J]. Int J Mol Sci，2018，19（2）：573．
本文引用 [1]
34
Borst O， Gawaz M. Glycoprotein Ⅵ - novel target in antiplatelet medication[J]. Pharmacol Ther，2021，217：107630．
本文引用 [1]
35
Cheng Q， Wang M， Jin R，et al. Blocking of PI3 - kinase beta protects against cerebral ischemia/reperfusion injury by reducing platelet activation and downstream microvascular thrombosis in rats[J]. Sci Rep，2023，13（1）：2030．
本文引用 [1]
36
Ren LJ， You T， Li Q，et al. Molecular docking-assisted screening reveals tannic acid as a natural protein disulphide isomerase inhibitor with antiplatelet and antithrombotic activities[J]. J Cell Mol Med，2020，24（24）：14257-14269．
本文引用 [1]
37
Savitz SI， Baron JC， Fisher M，et al. Stroke treatment academic industry roundtable X：brain cytoprotection therapies in the reperfusion era[J]. Stroke，2019，50（4）：1026-1031．
本文引用 [2]
38
Haupt M， Gerner ST， Bähr M，et al. Neuroprotective strategies for ischemic stroke-future perspectives[J]. Int J Mol Sci，2023，24（5）：4334．
本文引用 [1]
39
Lyden PD. Cerebroprotection for acute ischemic stroke：looking ahead[J]. Stroke，2021，52（9）：3033-3044．
本文引用 [1]
40
Hill MD， Goyal M， Menon BK，et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke（ESCAPE-NA1）：a multicentre，double-blind，randomised controlled trial[J]. Lancet，2020，395（10227）：878-887．
本文引用 [2]
41
Lee JS， Lee JS， Gwag BJ，et al. The rescue on reperfusion damage in cerebral infarction by nelonemdaz（RODIN） trial：protocol for a double-blinded clinical trial of nelonemdaz in patients with hyperacute ischemic stroke and endovascular thrombectomy[J]. J Stroke，2023，25（1）：160-168．
本文引用 [2]
42
Mariana F， Joana RP， Inês V，et al. Edaravone for acute ischemic stroke-Systematic review with meta-analysis[J]. Clin Neurol Neurosurg，2022，219：107299．
本文引用 [2]
43
Xu J， Wang AX， Meng X，et al. Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke：a phase Ⅲ，randomized，double-blind，comparative trial[J]. Stroke，2021，52（3）：772-780．
本文引用 [2]
44
Zhao KM， Wang PW， Tang XG，et al. The mechanisms of minocycline in alleviating ischemic stroke damage and cerebral ischemia-reperfusion injury[J]. Eur J Pharmacol，2023，955：175903．
本文引用 [2]
45
Lyden P， Pryor KE， Coffey CS，et al. Randomized，controlled，dose escalation trial of a protease-activated receptor-1 agonist in acute ischemic stroke： Final Results of the RHAPSODY trial[J]. Annals of neurology，2019，85(1)： 125-136.
本文引用 [2]
46
Gulati A， Agrawal N， Vibha D，et al. Safety and efficacy of sovateltide（IRL-1620） in a multicenter randomized controlled clinical trial in patients with acute cerebral ischemic stroke[J]. CNS Drugs，2021，35（1）：85-104．
本文引用 [2]
47
Wang AX， Jia BX， Zhang XL，et al. Efficacy and safety of butylphthalide in patients with acute ischemic stroke：a randomized clinical trial[J]. JAMA Neurol，2023，80（8）：851-859．
本文引用 [2]
48
Wu J， Wu J， Wang L，et al. Urinary Kallidinogenase plus rt-PA intravenous thrombolysis for acute ischemic stroke：a systematic review and Meta-analysis of randomized controlled trials[J]. Comput Math Methods Med，2022，2022：1500669．
本文引用 [2]
49
Yamaguchi S， Yoshida M， Horie N，et al. Stem cell therapy for acute/subacute ischemic stroke with a focus on intraarterial stem cell transplantation：from basic research to clinical trials[J]. Bioengineering，2022，10（1）：33．
本文引用 [1]
50
Ni J， Yao M， Wang LH，et al. Human urinary kallidinogenase in acute ischemic stroke：a single-arm，multicenter，phase Ⅳ study （RESK study）[J]. CNS Neurosci Ther，2021，27（12）：1493-1503．
本文引用 [1]
51
Malhotra K， Chang JJ， Khunger A，et al. Minocycline for acute stroke treatment：a systematic review and meta-analysis of randomized clinical trials[J]. J Neurol，2018，265（8）：1871-1879．
本文引用 [1]
52
Amaro S， Laredo C， Renú A，et al. Uric acid therapy prevents early ischemic stroke progression：a tertiary analysis of the URICO-ICTUS trial（efficacy study of combined treatment with uric acid and r-tPA in acute ischemic stroke）[J]. Stroke，2016，47（11）：2874-2876．
本文引用 [1]
53
Hernández-Jiménez M， Abad-Santos F， Cotgreave I，et al. Safety and efficacy of ApTOLL in patients with ischemic stroke undergoing endovascular treatment：a phase 1/2 randomized clinical trial[J]. JAMA Neurol，2023，80（8）：779-788．
本文引用 [1]

Comments

PDF(587 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Journal of Chongqing Medical University, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉